Thursday 16 October, 2025
Objectives: The standard pharmacometric approach of model selection ignores model uncertainty, potentially leading to impaired predictive performance, which may partially be…
Read moreAbstracts
Blood glucose profile evaluation with model-based approach using continuous glucose monitoring data
Thursday 16 October, 2025
Introduction: Continuous glucose monitoring (CGM) has revolutionized type 1 (T1D) and type 2 (T2D) diabetes management, as it provides real-time,…
Read moreVirtual Patient Populations: Comparison of Approaches in Application to QSP Model Of Erythropoiesis
Thursday 16 October, 2025
Introduction: In a standard situation, the QSP model describes some “reference patient”, i.e. the model parameters are fixed values, allowing…
Read moreA new approach to predict PFS in Ovarian Cancer based on tumor growth dynamics.
Thursday 16 October, 2025
Objectives: Progression free survival (PFS) is a surrogate efficacy endpoint that is being used for regulatory approval of investigational drugs…
Read moreThe new era of pharmacokinetic/pharmacodynamic modeling and simulation in drug development in Korea
Thursday 16 October, 2025
Introduction: As Korean pharmaceutical industry is reaching the golden era of drug discovery due to increased investments in R&D and…
Read morePopulation pharmacokinetics of benznidazole as monotherapy and in combination with fosravuconazole in adult patients with chronic Chagas disease (BENDITA study)
Thursday 16 October, 2025
Introduction: Chagas disease (American trypanosomiasis) is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi and can lead…
Read morePharmacokinetic-pharmacodynamic analysis of DNDi-6148 in pre-clinical models of visceral leishmaniasis
Thursday 16 October, 2025
Introduction: Visceral leishmaniasis (kala-azar) is a neglected tropical disease caused by Leishmania parasites (L. donovani and L. infantum) and can be…
Read moreA repeated time-to-event model linking infliximab clearance to the risk of relapse during maintenance treatment of patients with inflammatory bowel disease
Thursday 16 October, 2025
Objectives: Therapeutic drug monitoring (TDM) of intravenously administered infliximab is common practice in patients with inflammatory bowel disease (IBD). Dosing…
Read moreHigher clearance of therapeutic antibodies is associated with worse endoscopic outcomes in patients with Crohn’s disease
Thursday 16 October, 2025
Objectives: Monitoring of monoclonal antibody clearance has been hypothesized to be an appealing approach for predicting treatment outcomes in patients with…
Read morePharmacokinetic-Pharmacodynamic Model-Based Exploration of Alternative Ustekinumab Dosage Regimens for Patients with Crohn’s Disease
Thursday 16 October, 2025
Objectives: Ustekinumab is a fully human monoclonal antibody that is approved for the treatment of patients with moderate-to-severe Crohn’s disease…
Read more